NO20062118L - Inhibitor kontrastmidler - Google Patents

Inhibitor kontrastmidler

Info

Publication number
NO20062118L
NO20062118L NO20062118A NO20062118A NO20062118L NO 20062118 L NO20062118 L NO 20062118L NO 20062118 A NO20062118 A NO 20062118A NO 20062118 A NO20062118 A NO 20062118A NO 20062118 L NO20062118 L NO 20062118L
Authority
NO
Norway
Prior art keywords
contrast agents
inhibitor contrast
inhibitor
contrast
mmps
Prior art date
Application number
NO20062118A
Other languages
English (en)
Norwegian (no)
Inventor
Magne Solbakken
Alan Cuthbertson
Emma Bjurgert
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of NO20062118L publication Critical patent/NO20062118L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
NO20062118A 2003-11-14 2006-05-11 Inhibitor kontrastmidler NO20062118L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0326546.9A GB0326546D0 (en) 2003-11-14 2003-11-14 Inhibitor imaging agents
PCT/GB2004/004792 WO2005049005A1 (fr) 2003-11-14 2004-11-12 Agents inhibiteurs d'imagerie

Publications (1)

Publication Number Publication Date
NO20062118L true NO20062118L (no) 2006-05-11

Family

ID=29726529

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062118A NO20062118L (no) 2003-11-14 2006-05-11 Inhibitor kontrastmidler

Country Status (16)

Country Link
US (1) US20070104644A1 (fr)
EP (1) EP1682113B1 (fr)
JP (1) JP5043438B2 (fr)
KR (1) KR20060118479A (fr)
CN (1) CN1901894A (fr)
AT (1) ATE384519T1 (fr)
AU (1) AU2004290950A1 (fr)
BR (1) BRPI0416528A (fr)
CA (1) CA2545267A1 (fr)
DE (1) DE602004011553T2 (fr)
ES (1) ES2299884T3 (fr)
GB (1) GB0326546D0 (fr)
MX (1) MXPA06005355A (fr)
NO (1) NO20062118L (fr)
RU (1) RU2006117298A (fr)
WO (1) WO2005049005A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2007030012A2 (fr) * 2005-09-05 2007-03-15 Stichting Voor De Technische Wetenscahappen Mise en image d'une matrice extracellulaire
FR2891830B1 (fr) 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
GB0520527D0 (en) * 2005-10-10 2005-11-16 Ge Healthcare Ltd Automated method
CN101379023A (zh) 2006-02-15 2009-03-04 通用电气医疗集团股份有限公司 造影剂
KR20080104347A (ko) * 2006-03-29 2008-12-02 노파르티스 아게 선택적 히드록사메이트-기재 mmp 억제제
WO2007110449A1 (fr) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Composés de benzènesulfonamide et utilisation de ceux-ci
WO2007118854A1 (fr) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Composés à base de benzènesulfonamide et leur utilisation
WO2007118853A1 (fr) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzènesulfonamides et leur emploi en tant qu'agents bloquants des canaux calcium
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
JP2010513476A (ja) * 2006-12-20 2010-04-30 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
WO2008124118A1 (fr) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Composés benzènesulfonylés et leur utilisation
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
EP2119690A1 (fr) 2008-05-14 2009-11-18 Academisch Medisch Centrum bij de Universiteit van Amsterdam Composants sélectifs MMP radiomarqués
JP5322527B2 (ja) * 2008-07-17 2013-10-23 浜松ホトニクス株式会社 アポトーシスの検出に適した化合物
EP2147684A1 (fr) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Agents de diagnostics sélectifs contre les métalloprotéases
WO2010138720A2 (fr) * 2009-05-27 2010-12-02 The Scripps Research Institute Composés et procédés de chélation de métaux en solutions aqueuses
WO2011000958A1 (fr) 2009-07-03 2011-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Composés ciblant le récepteur du mannose 6-phosphate cation indépendant
WO2011059696A2 (fr) 2009-10-29 2011-05-19 The Procter & Gamble Company Composition d'après-shampooing comprenant un système tensioactif cationique, un colorant direct et un épaississant non ionique
US9023318B2 (en) * 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
US8871189B2 (en) * 2011-11-30 2014-10-28 Mallinckrodt Llc MMP-targeted therapeutic and/or diagnostic nanocarriers
CN103980277B (zh) * 2014-05-27 2016-06-15 青岛大学 一种叶酸巯基化衍生物的制备方法
GB202012671D0 (en) * 2020-08-13 2020-09-30 Nrf Ithemba Labs Theranostic Compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714465A (en) * 1989-05-19 1998-02-03 Amgen Inc. Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0895988T3 (da) * 1997-08-08 2002-09-09 Pfizer Prod Inc Arylsulfonylaminohydroxamsyrederivater
EA002490B1 (ru) * 1997-08-08 2002-06-27 Пфайзер Продактс Инк. Производные арилоксиарилсульфониламиногидроксамовой кислоты
IL127496A0 (en) * 1997-12-19 1999-10-28 Pfizer Prod Inc The use of MMP inhibitors for the treatment of ocular angiogenesis
ATE266634T1 (de) * 1998-04-10 2004-05-15 Pfizer Prod Inc Cyclobutyl-aryloxysulfonylamin- hydroxamsäurederivate
US6677355B1 (en) * 1999-08-18 2004-01-13 Warner-Lambert Company Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors
IL138686A0 (en) * 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
AU2001265182A1 (en) * 2000-05-30 2001-12-11 Rafael Fridman Inhibitors of matrix metalloproteinases
EP1592458A1 (fr) * 2003-02-10 2005-11-09 GE Healthcare Limited Agents d'imagerie diagnostiques a activite inhibitrice de mmp

Also Published As

Publication number Publication date
DE602004011553T2 (de) 2009-03-26
US20070104644A1 (en) 2007-05-10
WO2005049005A1 (fr) 2005-06-02
EP1682113B1 (fr) 2008-01-23
ES2299884T3 (es) 2008-06-01
DE602004011553D1 (de) 2008-03-13
GB0326546D0 (en) 2003-12-17
JP5043438B2 (ja) 2012-10-10
BRPI0416528A (pt) 2007-01-09
CA2545267A1 (fr) 2005-06-02
JP2007511494A (ja) 2007-05-10
CN1901894A (zh) 2007-01-24
MXPA06005355A (es) 2006-07-10
KR20060118479A (ko) 2006-11-23
RU2006117298A (ru) 2007-12-20
EP1682113A1 (fr) 2006-07-26
ATE384519T1 (de) 2008-02-15
AU2004290950A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
NO20062118L (no) Inhibitor kontrastmidler
NO20072120L (no) Enzyme Inhibitor Imaging Agents
EA201000542A1 (ru) Способы, устройства, системы, комплекты и наборы для отведения тканей в ротовой полости
RS51213B (sr) Farmaceutski vaginalni gel koji sadrži tenofovir
UY27972A1 (es) Derivados de hidantoína
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
ATE418967T2 (de) Matrix für die modifizierte freigabe von aktiven substanzen
BRPI0414030A (pt) método para detectar desordens neoplásicas em uma amostra corporal solubilizada
DK1751108T3 (da) Adamantyl-acetamidderivater som inhibitorer for 11-beta-hydroxysteroid-dehydrogenase-type 1-enzymet
DE602005003570D1 (de) Rohr- und universalkupplung für die zufuhr von zahnmedizinischen oder chirurgischen instrumenteen
DE60305906D1 (de) Okklusionszusammensetzung umfassend ein poly(2-cyanoacrylat)-monomer
TW200617174A (en) Method of diagnosing lawsonia intracellularis
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
ATE519505T1 (de) Reaktive paramagnetische kontrastmittel für magnetresonanzbildgebung
NO20054049D0 (no) Fremgangsmate for diagnose og behandling.
DE60234821D1 (de) Messverfahren für vollblut
BRPI0515161A (pt) substratos enzimáticos derivados de fenoxazinona e seu uso como revelador na detecção de microorganismos com atividade de peptidase
WO2006124866A3 (fr) Dosage immunoenzymetrique ige de serum humain libre
EA200801875A1 (ru) Антагонист cd 80
NZ597557A (en) Mycobacterial disease detection, treatment, and drug discovery
WO2001088533A3 (fr) Dosages d'absorption de lipides
BR0317404A (pt) Variantes do fator xiia
ITMI20021976A1 (it) Procedimento e dispositivo per la diagnosi di uno smorzatore di pressioni.
ITTO20040345A1 (it) Apparecchio di prova per l'esecuzione di prove hdt e vicat.
SE0202608D0 (sv) New sequences

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application